Plasma Biomarkers Shift Alzheimer’s Diagnosis Toward Biology Over Symptoms
Plasma biomarkers for Alzheimer’s disease are transforming clinical diagnosis by moving the medical focus from late-stage cognitive symptoms to early underlying pathology, as reported from the Brazilian Congress of Neurology (NEURO26) in Rio de Janeiro. While traditional evaluations relied heavily on identifying cognitive syndromes, newly validated blood tests allow clinicians to detect biological changes years before symptoms appear. This shift introduces both diagnostic accuracy and complex interpretive challenges regarding staging and patient eligibility for emerging therapies. The diagnostic framework shifted significantly when the Alzheimer’s Association published revised criteria establishing a biological definition of the disease using core biomarkers like amyloid PET and specific cerebrospinal fluid protein ratios. However, divergent recommendations from the International Working Group emphasize that positive biomarkers in cognitively normal individuals represent a state of risk rather than an immediate clinical diagnosis.
Diagnostic Accuracy of Phosphorylated Tau 217
Phosphorylated tau at threonine 217 (p-tau217) has emerged as a blood-based biomarker closely linked to cerebral beta-amyloid deposition in early pathological cascades. A prospective study published by Palmqvist and collaborators in PEOPLE in 2024 evaluated 1,213 patients in primary and specialized care, finding that a blood test utilizing the p-tau217 percentage ratio achieved approximately 91% accuracy for identifying clinical Alzheimer’s in patients with mild cognitive impairment or dementia. This significantly outperformed the 61% accuracy of conventional clinical evaluations conducted by primary care physicians. Performance varies considerably depending on specific assay platforms, absolute concentrations, and chosen cutoffs.
Clinical Implementation and Regulatory Approvals in Brazil
Regulatory milestones have accelerated the integration of these tests into clinical practice, highlighted by the authorization of the Lumipulse G pTau 217 Plasma assay by Anvisa in September 2026. Guidelines published by the Alzheimer’s Association specify that screening tools require a minimum sensitivity of 90% and specificity of 75%, while diagnostic alternatives to PET or cerebrospinal fluid analysis must reach at least 90% for both parameters.
Combining Biomarkers for Disease Staging
Researchers are expanding beyond amyloid detection by utilizing novel markers like eMTBR-tau243 to track neurofibrillary tangle load and disease staging. A 2026 study in The Lancet Neurology by Mattsson-Carlgren and colleagues demonstrated that integrating p-tau217 and eMTBR-tau243 raised the positive predictive value to 84% in patients with cognitive symptoms.
Diagnostics Fit Within Organized Medical Workflows
These combined measures ensure that blood-based diagnostics fit securely within an organized medical workflow rather than serving as isolated verification steps.
Frequently Asked Questions About Alzheimer’s Plasma Biomarkers
What specific blood test received regulatory approval in Brazil?
Anvisa authorized the commercialization of the Lumipulse G pTau 217 Plasma assay by Fujirebio in September 2026 for clinical use.
How accurate are plasma biomarker tests compared to standard primary care evaluations?
A 2024 study published in PEOPLE by Palmqvist and colleagues found that blood tests using p-tau217 achieved an accuracy of approximately 91% for identifying clinical Alzheimer’s, compared to 61% for conventional clinical evaluations by primary care physicians.
Keep reading